Pharmaceutical giant Lilly, ib lub tuam txhab Asmeskas, thiab Novo Nordisk, lub tuam txhab Danish, tau tshaj tawm cov ntaub ntawv muag khoom ntawm lawv cov khoom tseem ceeb hauv xyoo 2020: Dulaglutide tau dhau los ua TOP1 GLP-1 tshuaj, nrog muag ntawm $ 5.07Bn hauv 2020, ib xyoos- nce xyoo ntawm 22.8%;liraglutide Pib nkag mus rau lub sijhawm poob qis, kev muag khoom hauv 2020 tau nqis los ntawm $ 4.14Bn rau $ 3.93Bn, ib xyoos ib zaug txo ntawm 5.1%;semaglutide tau loj hlob sai tshaj plaws, nrog kev muag khoom mus txog $ 3.72Bn hauv 2020, ib xyoos ib zaug nce ntawm 119.9%.
Lilly's dulaglutide (lub npe lag luam Trulicity®) tau tsim tawm hauv xyoo 2014 thiab tau los ua cov tshuaj blockbuster nrog muag ntawm $ 5.07Bn hauv tsuas yog 6 xyoo, dhau los ua tus muag khoom ntawm GLP-1 tshuaj.Novo Nordisk cov khoom lag luam ib ntus tau poob qis tom qab Lilly.Nws liraglutide (lub npe lag luam Victoza® thiab Saxenda®), uas tau tsim tawm hauv 2009, yog ib zaug muag tau yeej ntawm GLP-1 cov tshuaj, thiab nws cov khoom muag siab tshaj plaws hauv 2017 tau txog $ 4.37Bn, txawm hais tias muaj ob qhov qhia rau hom II ntshav qab zib thiab rog rog. , cov ntaub ntawv rau xyoo 2020 qhia tias kev ua lag luam rau cov tshuaj no tau nkag mus rau lub sijhawm poob.Tib lub Novo Nordisk's semaglutide (cov npe lag luam Ozempic® thiab Rybelsus®) tau loj hlob sai thiab tau loj hlob mus rau lwm cov tshuaj blockbuster nrog muag ntawm $ 3.72Bn hauv peb xyoos.Cov tshuaj muaj ob hom kev txhaj tshuaj thiab kev npaj ntawm qhov ncauj.
Los ntawm qhov kev xav ntawm thaj chaw, Tebchaws Meskas yog lub tebchaws muag khoom tseem ceeb ntawm liraglutide, suav txog ze li ntawm 60% hauv 2020, ib xyoos ib zaug txo ntawm 11.02%;nws kuj yog qhov kev poob qis hauv Tebchaws Meskas uas tau ua rau muaj kev poob qis hauv kev lag luam thoob ntiaj teb rau liraglutide.EMEA (Tebchaws Europe, Middle East, Africa) cheeb tsam tau loj hlob qeeb, nrog CAGR tsuas yog 1.6% hauv tsib xyoos dhau los;Tuam Tshoj yog lub lag luam loj tshaj plaws, nrog kev muag khoom ntawm $ 182.50Mn hauv xyoo 2020, nrog kev loj hlob txhua xyoo ntawm 42.39%.Txij li thaum semaglutide tau nyob rau hauv kev ua lag luam sai sai, tag nrho cov kev lag luam nyob rau hauv ib theem ntawm kev loj hlob sai.Tebchaws Asmeskas tseem yog lub lag luam loj tshaj plaws, suav txog 80.04% ntawm kev muag khoom hauv xyoo 2020, nce xyoo 106.08%;EMEA tsuas muaj 13.64% feem ntau tab sis kev loj hlob ib xyoos ib zaug ntawm 249.65% %.Semaglutide tau tsim tawm hauv Suav teb xyoo 2020 nrog kev muag khoom ntawm $ 1.61Mn.Daim duab 3 qhia txog qhov xwm txheej hauv cheeb tsam ntawm dulaglutide.Raws li lub lag luam loj tshaj plaws, Tebchaws Asmeskas muaj kev muag khoom siab txog $ 3.836Bn, suav txog 75.69%, nrog rau kev loj hlob txhua xyoo ntawm 79.18%.
Cov tseem ceeb patents rau liraglutide (Victoza® thiab Saxenda®) tau tas sij hawm nyob rau hauv Tuam Tshoj thiab tab tom yuav tas rau hauv Teb Chaws Asmeskas, Nyiv thiab Lub Tebchaws Yelemees.Teva's patent sib ntaus sib tua nrog Novo Nordisk tau txiav txim siab, thiab Teva's generic version yuav muaj nyob rau hauv 2023. Mylan kuj tau ua ntawv thov ANDA nrog FDA rau liraglutide nrog PIV thov.Nrog rau qhov maj mam tas sij hawm ntawm cov tseem ceeb patents thiab kev hem thawj ntawm cov tuam txhab tshuaj generic, cov tshuaj yuav maj mam nkag mus rau lub sijhawm poob.Teb Chaws Asmeskas patent ntawm Trulicity® yuav tsis tas mus txog rau xyoo 2027, thaum lub sij hawm sib xyaw patents ntawm cov teb chaws Europe loj thiab Nyij Pooj yuav tsis tas mus txog rau xyoo 2029, thiab cov tseem ceeb patent tiv thaiv ntev dua liraglutide.Cov patents tseem ceeb ntawm semaglutide (Ozempic® thiab Rybelsus®) yuav tas rau xyoo 2032 thaum kawg, thiab tseem muaj chaw zoo rau kev lag luam loj hlob, tab sis nws lub sij hawm tas sij hawm hauv Suav teb yog 2026.
Post lub sij hawm: Lub Xya hli ntuj-25-2022